Skip to main content
Clinical Trials/EUCTR2005-003997-74-DK
EUCTR2005-003997-74-DK
Active, not recruiting
Phase 1

Depletion of regulatory T-lymphocytes by intratumoral injection of antibodies.

Rigshospitalet0 sites30 target enrollmentJanuary 10, 2006

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Not specified
Sponsor
Rigshospitalet
Enrollment
30
Status
Active, not recruiting
Last Updated
9 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
January 10, 2006
End Date
TBD
Last Updated
9 years ago
Study Type
Interventional clinical trial of medicinal product
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • Histopathologically verified cancer with metastasis. No further conventional anti\-cancer treatment options.
  • Radiological visualisation of cancer/metastasis localisation must enable direct or ultrasonography mediated intratumoral injection
  • Cancer diseases preferred:
  • 1\. liver, primary and secondary.
  • 2\. mammary cancer
  • 3\. sarcomas
  • 4\. melanomas
  • 5\. prostate
  • 6\. kidney, hypernefroma
  • Are the trial subjects under 18? yes

Exclusion Criteria

  • Expected lifetime \< 3 months
  • ECOG 3\-4\.
  • Ongoing infection
  • \< 4 weeks from prior immunosuppressive therapy
  • Billirubin \>2 times upper normal value
  • ASAT/ALAT \>2 times upper normal value
  • abnormal creatinine
  • \< 4 weeks from major surgery
  • positive pregnancy test
  • No use of safe barrier contraception

Outcomes

Primary Outcomes

Not specified

Similar Trials